Ashford Capital Management Inc. Trims Stock Position in Lantheus Holdings, Inc. (NASDAQ:LNTH)

Ashford Capital Management Inc. lessened its holdings in shares of Lantheus Holdings, Inc. (NASDAQ:LNTH - Free Report) by 12.3% in the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 94,650 shares of the medical equipment provider's stock after selling 13,280 shares during the period. Ashford Capital Management Inc. owned 0.14% of Lantheus worth $10,388,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also recently made changes to their positions in the company. Janus Henderson Group PLC increased its position in shares of Lantheus by 7.7% during the third quarter. Janus Henderson Group PLC now owns 3,588,571 shares of the medical equipment provider's stock valued at $393,844,000 after acquiring an additional 257,022 shares during the last quarter. Farallon Capital Management LLC boosted its stake in shares of Lantheus by 53.7% in the 2nd quarter. Farallon Capital Management LLC now owns 2,279,227 shares of the medical equipment provider's stock valued at $182,999,000 after buying an additional 796,000 shares during the period. Geode Capital Management LLC increased its position in shares of Lantheus by 2.0% in the 3rd quarter. Geode Capital Management LLC now owns 1,683,500 shares of the medical equipment provider's stock valued at $184,798,000 after purchasing an additional 32,551 shares during the last quarter. Dimensional Fund Advisors LP raised its holdings in shares of Lantheus by 1.6% in the 2nd quarter. Dimensional Fund Advisors LP now owns 1,239,502 shares of the medical equipment provider's stock valued at $99,525,000 after purchasing an additional 19,071 shares in the last quarter. Finally, Swedbank AB grew its stake in shares of Lantheus by 21.1% during the third quarter. Swedbank AB now owns 722,243 shares of the medical equipment provider's stock worth $79,266,000 after purchasing an additional 125,843 shares in the last quarter. Institutional investors and hedge funds own 99.06% of the company's stock.

Lantheus Stock Performance

LNTH traded down $1.60 on Tuesday, hitting $90.98. 1,090,606 shares of the company were exchanged, compared to its average volume of 1,015,578. Lantheus Holdings, Inc. has a fifty-two week low of $50.20 and a fifty-two week high of $126.89. The firm has a market capitalization of $6.33 billion, a P/E ratio of 15.40 and a beta of 0.45. The business's fifty day moving average is $99.04 and its 200 day moving average is $97.75.

Wall Street Analysts Forecast Growth

A number of analysts have issued reports on the company. JMP Securities decreased their price target on Lantheus from $125.00 to $112.00 and set a "market outperform" rating for the company in a report on Thursday, November 7th. Redburn Atlantic began coverage on shares of Lantheus in a report on Tuesday, September 3rd. They issued a "buy" rating and a $175.00 target price for the company. StockNews.com cut shares of Lantheus from a "buy" rating to a "hold" rating in a research report on Thursday, November 21st. Finally, Truist Financial reaffirmed a "buy" rating and set a $120.00 price target (down previously from $135.00) on shares of Lantheus in a research report on Friday, November 8th. Two research analysts have rated the stock with a hold rating and six have given a buy rating to the stock. Based on data from MarketBeat.com, the company has an average rating of "Moderate Buy" and a consensus price target of $130.00.

Lantheus Profile

Lantheus Holdings, Inc develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer.